Jagsonpal Pharmaceuticals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Jagsonpal Pharmaceuticals Ltd filed with BSE on 04 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jagsonpal Pharmaceuticals reported Q1 FY27 revenue growth of about 9% year-on-year to Rs.82 crores, with operating EBITDA up around 21% to close to Rs.19 crores and PAT up 22% to Rs.13 crores. The company completed an 85% stake acquisition in Aequitas Healthcare for Rs.20.8 crores, giving it entry into the hospital pharmaceutical segment, and also completed a Rs.40 crores share buyback during the quarter. Management described organic growth initiatives around brand-building, productivity improvement, and portfolio shift toward semi-chronic and specialty therapies.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: Rs.82 crores (Q1 FY27)
p. 7
“Revenue from operations increased close to 9% year-on-year to Rs.82 crores, while gross profit grew over 10% to Rs.54 crores, with gross margins improving to 65%-plus.”
Nirav Vora, page 7 of the filed PDF · View the filing
Operating EBITDA: close to Rs.19 crores (Q1 FY27)
p. 7
“Operating EBITDA increased by around 21%, standing close to Rs.19 crores, with margins above 23%-plus, expanding by 240 bps.”
Nirav Vora, page 7 of the filed PDF · View the filing
PAT: Rs.13 crores (Q1 FY27)
p. 7
“PAT grew by 22% to Rs.13 crores, while margins improved by 176 bps to 16%.”
Nirav Vora, page 7 of the filed PDF · View the filing
Closing cash balance: Rs.170 crores (Q1 FY27)
p. 7
“thereby maintaining a healthy closing cash balance of Rs.170 crores.”
Nirav Vora, page 7 of the filed PDF · View the filing
Aequitas acquisition consideration: Rs.20.8 crores
p. 7
“I am pleased to share that we have successfully completed the acquisition of 85% stake in Aequitas Healthcare for a consideration of Rs.20.8 crores.”
Nirav Vora, page 7 of the filed PDF · View the filing
Aequitas FY26 revenue: Rs.53 crores (FY26)
p. 4
“With FY26 revenue of Rs.53 crores, Aequitas provides JPL an immediate and meaningful entry into the hospital segment, thereby creating new opportunities through hospital formulary access, cross tselling and operating synergies.”
Manish Gupta, page 4 of the filed PDF · View the filing
Sales growth (JPL vs industry, Pharmarack): 18.9% vs 11.6% (Q1 FY27)
p. 3
“The strong performance is also reflecting in the Pharmarackdata where JPL grew by about 18.9% in the quarter as against the industry growth of 11.6% in the period.”
Manish Gupta, page 3 of the filed PDF · View the filing
Return on capital employed improvement: 340 bps (Q1 FY27)
p. 4
“we completed a Rs.40 crores share buyback which has strong positive impact on our already healthy return on capital employed by another 340 bps.”
Manish Gupta, page 4 of the filed PDF · View the filing
Power brand portfolio growth: 19% vs market growth of 16% (Q1 FY27)
p. 6
“Our power brand portfolio is also reflecting a growth of 19% versus the market growth of 16%.”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Maintane brand value (Pharmarack): Rs.46 crores
p. 11
“I can tell you what is coming in the public domain, which is Pharmarack numbers, which talks about a value of close to around Rs.46 crores is what it is showing in Pharmarack.”
Amrut Medhekar, page 11 of the filed PDF · View the filing
Operating cash generated over last four years: over Rs.250 crores (FY22-FY26)
p. 8
“During this period, we have generated over Rs.250 crores of operating cash, which has been judiciously deployed towards strategic acquisitions, including Yash Pharma for over Rs.90 crores, as well as shareholders' returns through a dividend of over Rs.40 crores and buyback of Rs.40 crores.”
Nirav Vora, page 8 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Growth relative to industry — 1.5x industry growth rate · quarters to come
stated as an aspiration by Manish Gupta
p. 3
“I do believe that we are now on track of getting our growth to 1.5x industry growth rate in the quarters to come.”
Manish Gupta, page 3 of the filed PDF · View the filing
Aequitas EBITDA — Rs.10 crores EBITDA · year two post-integration
stated firmly by Amrut Medhekar
p. 7
“Starting with a revenue base of Rs.53 crores, we are targeting Rs.10 crores EBITDA by year two post-integration, driving higher revenue contribution and improving profitability from FY27.”
Amrut Medhekar, page 7 of the filed PDF · View the filing
Aequitas revenue scale — around Rs.100 crores · two and a half years
stated as an aspiration by Amrut Medhekar
p. 13
“Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.”
Amrut Medhekar, page 13 of the filed PDF · View the filing
Growth target vs industry — breach 1.5x of promise vs Indian pharma industry
stated firmly by Amrut Medhekar
p. 9
“we continue to maintain our guidance that our objective will be to breach this 1.5x of our promise as compared to the Indian pharma industry.”
Amrut Medhekar, page 9 of the filed PDF · View the filing
People productivity (PCPM) — upward of 2,50,000
stated as an aspiration by Amrut Medhekar
p. 12
“we are targeting upward of 2,50,000 in terms of people productivity.”
Amrut Medhekar, page 12 of the filed PDF · View the filing
Aequitas synergies — next 36-months
stated firmly by Amrut Medhekar
p. 6
“Due diligence was done, integration planning is already underway and we expect the projected synergies to create significant value over the next 36-months.”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management cited the brand's hospital reputation, cross-selling opportunities, retained promoter involvement, and new product launches as drivers.
Answered by Amrut Medhekar
Asked by Mihir: Can you give more detail on how Aequitas EBITDA will grow from Rs.50 lakhs to Rs.10 crores?
p. 9
“So, this is primarily a brand asset which has a very good reputation in the hospital pharmaceutical supply business.”
Amrut Medhekar, page 9 of the filed PDF · View the filing
Management said there have been no surprises due to thorough due diligence, and expects numbers to show results within a couple of quarters.
Answered by Amrut Medhekar
Asked by Sajal Kapoor: What is the earliest evidence that Aequitas integration is working, and what has surprised management most?
p. 10
“I am pretty sure about it that numbers will speak maybe in the next two quarters.”
Amrut Medhekar, page 10 of the filed PDF · View the filing
Management said Aequitas has a longer working capital cycle than JPL and will not be aligned to JPL's cycle, though improvements are intended.
Answered by Manish Gupta
Asked by Neelam: What is the working capital cycle like for Aequitas compared to JPL?
p. 13
“Clearly, Aequitas working capital cycle is longer than JPL. We intend to improve it, but it will not get aligned with JPL.”
Manish Gupta, page 13 of the filed PDF · View the filing
Management attributed it mainly to inventory control and stricter collection and creditor payment practices, with the larger step-change occurring between FY22 and FY24.
Answered by Manish Gupta
Asked by Sajal Kapoor: What drove the dramatic improvement in working capital days since FY24?
p. 16
“Sajal, I think if you look at the data, our larger dip in working capital came between FY22 to FY24. Cash conversion days dropped from 59-days to 22-days.”
Manish Gupta, page 16 of the filed PDF · View the filing
Management said hospital business margins are thinner because price, not brand, drives purchasing decisions in that channel.
Answered by Amrut Medhekar
Asked by Anubhav Mukherjee: Why is Aequitas's gross margin lower than JPL's branded business?
p. 17
“For a hospital business, it will be like this. The margins will be much thinner versus a branded prescription business, because there you have doctors choice towards or buyers towards a particular brand due to its name, image, quality associated with it over a long-term use.”
Amrut Medhekar, page 17 of the filed PDF · View the filing
Risks flagged
Variance between reported secondary sales data and actual company sales due to statistical representation issues
p. 8
“These variances should not have been so higher. We are looking into it as to why this has happened.”
Amrut Medhekar, page 8 of the filed PDF · View the filing
Hospital business margins under pressure due to price-driven purchasing by corporate hospital chains
p. 17
“So, largely if you look at, all the large organizations will have similar kind of quality, all the large companies and good companies, but what makes the difference in terms of which brand they will have choice to stock would be the price.”
Amrut Medhekar, page 17 of the filed PDF · View the filing
Attrition as an industry-wide constraint on growth
p. 6
“One of the significant constraints of growth for the industry has been attrition.”
Amrut Medhekar, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.